
Alphatec Hlds (ATEC) Stock Forecast & Price Target
Alphatec Hlds (ATEC) Analyst Ratings
Bulls say
Alphatec Holdings, Inc. reported Q2 2025 revenues of $185.5 million, reflecting a robust year-over-year increase of 27.5% and exceeding consensus estimates. This growth was supported by a 28% rise in surgical volume, driven by both the recruitment of new surgeons and enhanced relationships with existing users. Additionally, the company raised its full-year 2025 revenue guidance to $742 million, representing a projected 21% year-over-year growth, showcasing strong operational momentum.
Bears say
Alphatec Holdings Inc has experienced a decline in its non-GAAP gross margin, which fell to 69.9%, a decrease of 130 basis points year-over-year and 50 basis points sequentially, primarily due to changes in product mix and increased biologic attach rates within its cervical business segment. The company faces additional challenges from the evolving US healthcare landscape, particularly the risk of decreasing reimbursement rates that could adversely affect its revenue. Furthermore, there are concerns regarding the company's ability to meet future expectations, raising further uncertainty about its financial stability and growth prospects.
This aggregate rating is based on analysts' research of Alphatec Hlds and is not a guaranteed prediction by Public.com or investment advice.
Alphatec Hlds (ATEC) Analyst Forecast & Price Prediction
Start investing in Alphatec Hlds (ATEC)
Order type
Buy in
Order amount
Est. shares
0 shares